Trillium Therapeutics (Trillium Therapeutics) Total Assets : $265.36 Mil (As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Total Assets?

Trillium Therapeutics's Total Assets for the quarter that ended in Sep. 2021 was $265.36 Mil.

During the past 12 months, Trillium Therapeutics's average Total Assets Growth Rate was 160.90% per year. During the past 3 years, the average Total Assets Growth Rate was -1.10% per year. During the past 5 years, the average Total Assets Growth Rate was 8.70% per year. During the past 10 years, the average Total Assets Growth Rate was 53.50% per year.

During the past 13 years, Trillium Therapeutics's highest 3-Year average Total Assets Growth Rate was 209.80%. The lowest was -67.00%. And the median was -1.90%.

Total Assets is connected with ROA %. Trillium Therapeutics's annualized ROA % for the quarter that ended in Sep. 2021 was -28.67%. Total Assets is also linked to Revenue through Asset Turnover. Trillium Therapeutics's Asset Turnover for the quarter that ended in Sep. 2021 was 0.00.

Trillium Therapeutics Total Assets Historical Data

The historical data trend for Trillium Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Total Assets Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Assets

Get a 7-Day Free Trial

49.57

74.92

40.78

26.39

300.82

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Total Assets	Get a 7-Day Free Trial															297.80	300.82	288.29	273.68	265.36

Trillium Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Trillium Therapeutics's Total Assets for the fiscal year that ended in Dec. 2020 is calculated as

Total Assets	=	Total Equity (A: Dec. 2020 )	+	Total Liabilities (A: Dec. 2020 )
	=	278.847	+	21.975
	=	300.82

Trillium Therapeutics's Total Assets for the quarter that ended in Sep. 2021 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2021 )	+	Total Liabilities (Q: Sep. 2021 )
	=	243.161	+	22.199
	=	265.36

Trillium Therapeutics (NAS:TRIL) Total Assets Explanation

Total Assets is connected with ROA %.

Trillium Therapeutics's annualized ROA % for the quarter that ended in Sep. 2021 is

ROA %	=	Net Income (Q: Sep. 2021 )	/	( (Total Assets (Q: Jun. 2021 )	+	Total Assets (Q: Sep. 2021 ))	/ count )
	=	-77.264	/	( (273.684	+	265.36)	/ 2 )
	=	-77.264	/	269.522
	=	-28.67 %

Note: The Net Income data used here is four times the quarterly (Sep. 2021) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Trillium Therapeutics's Asset Turnover for the quarter that ended in Sep. 2021 is

	Asset Turnover
=	Revenue (Q: Sep. 2021 )	/	( (Total Assets (Q: Jun. 2021 )	+	Total Assets (Q: Sep. 2021 ))	/ count )
=	0	/	( (273.684	+	265.36)	/ 2 )
=	0	/	269.522
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Trillium Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.